Bachem Holding AG Class B (CH:BANB)
:BANB
Want to see CH:BANB full AI Analyst Report?
Top Page
Bachem Holding AG
(BANB)
Select Model
Select Model
Rating:77Outperform
Price Target:
CHF76.00
▲(8.34% Upside)
Action:Upgraded
Date:05/07/26
The score is driven primarily by a very strong, low-leverage balance sheet and solid profitability, partially tempered by persistent negative free cash flow and uneven cash conversion. Technicals are constructive with clear trend strength, but near-overbought signals add some short-term risk. Valuation is supportive with a relatively low P/E and a modest dividend yield.
Positive Factors
Conservative balance sheet
Extremely low leverage and a growing equity base give Bachem durable financial resilience. This conservatism supports investment in capacity, cushions biotech customer payment cycles, preserves borrowing optionality for large projects and reduces insolvency risk over multi-quarter horizons.
Negative Factors
Persistent negative free cash flow
Chronic negative free cash flow signals that investment and/or working-capital demands consistently outpace operating cash generation. Over time this can constrain internal financing for capacity adds, dividends or buybacks and may force reliance on external funding despite low leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Extremely low leverage and a growing equity base give Bachem durable financial resilience. This conservatism supports investment in capacity, cushions biotech customer payment cycles, preserves borrowing optionality for large projects and reduces insolvency risk over multi-quarter horizons.
Read all positive factors
Bachem Holding AG (BANB) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF4.92B
Dividend Yield1.43%
Average Volume (3M)109.83K
Price to Earnings (P/E)33.8
Beta (1Y)0.77
Revenue Growth14.84%
EPS Growth23.77%
CountryCH
Employees2,207
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.99
Shares Outstanding75,000,000
10 Day Avg. Volume97,857
30 Day Avg. Volume109,830
Financial Highlights & Ratios
PEG Ratio1.27
Price to Book (P/B)3.08
Price to Sales (P/S)6.46
P/FCF Ratio-93.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF86.67Price Target Upside23.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)2.36
Revenue Forecast (FY)CHF948.52M
Bachem Holding AG Business Overview & Revenue Model
Company Description
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support fo...
How the Company Makes Money
Bachem primarily makes money by selling peptide-based pharmaceutical ingredients and by providing contract development and manufacturing services. A major revenue stream is the manufacture and supply of peptide APIs for customers’ marketed drugs (...
Bachem Holding AG Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 695.07M | 605.26M | 577.32M | 531.74M | 503.23M |
| Gross Profit | 199.73M | 182.56M | 176.96M | 171.28M | 166.73M |
| EBITDA | 189.88M | 178.76M | 163.28M | 160.54M | 156.47M |
| Net Income | 148.79M | 120.25M | 111.86M | 100.68M | 114.68M |
Balance Sheet | |||||
| Total Assets | 2.11B | 1.92B | 1.68B | 1.38B | 1.30B |
| Cash, Cash Equivalents and Short-Term Investments | 30.99M | 95.20M | 298.53M | 268.43M | 442.36M |
| Total Debt | 57.39M | 290.00K | 401.00K | 691.00K | 20.86M |
| Total Liabilities | 650.41M | 531.88M | 362.36M | 214.21M | 177.50M |
| Stockholders Equity | 1.46B | 1.39B | 1.32B | 1.17B | 1.12B |
Cash Flow | |||||
| Free Cash Flow | -48.20M | -138.30M | -18.54M | -49.76M | -19.66M |
| Operating Cash Flow | 271.36M | 146.32M | 249.86M | 92.59M | 97.16M |
| Investing Cash Flow | -325.22M | -148.88M | -170.81M | -63.17M | -469.13M |
| Financing Cash Flow | -9.52M | -61.26M | 48.69M | -86.93M | 437.58M |
Bachem Holding AG Technical Analysis
Neutral
70.15
Price Trends
71.54
Negative
67.09
Positive
62.10
Positive
Market Momentum
-2.03
Positive
39.55
Neutral
24.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BANB, the sentiment is Neutral. The current price of 70.15 is below the 20-day moving average (MA) of 71.93, below the 50-day MA of 71.54, and above the 200-day MA of 62.10, indicating a neutral trend. The MACD of -2.03 indicates Positive momentum. The RSI at 39.55 is Neutral, neither overbought nor oversold. The STOCH value of 24.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:BANB.
Bachem Holding AG Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | CHF4.92B | 33.80 | 9.76% | 1.43% | 14.84% | 23.77% | |
77 Outperform | CHF4.74B | 17.03 | 27.15% | 0.67% | -2.39% | 154.37% | |
62 Neutral | CHF3.02B | 17.38 | 15.79% | 0.51% | 2.57% | 4.31% | |
61 Neutral | CHF4.21B | 23.22 | ― | 2.36% | 5.47% | -0.96% | |
56 Neutral | CHF33.69B | -125.89 | ― | 0.75% | -0.65% | -143.04% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | CHF1.17B | -62.01 | ― | ― | 13.85% | -7.03% |
* General Sector Average
CH:BANB
Bachem Holding AG
67.10
10.08
17.69%
CH:LONN
Lonza Group Ltd
493.30
-60.49
-10.92%
CH:SFZN
Siegfried Holding AG
67.00
-26.62
-28.43%
CH:YPSN
Ypsomed Holding AG
348.00
-51.38
-12.87%
CH:PPGN
PolyPeptide Group AG
36.55
15.40
72.81%
CH:GALE
Galenica AG
84.40
0.93
1.12%
Bachem Holding AG Corporate Events
Bachem Plans Hybrid Capital Markets Day in Zurich for 2026
Jun 12, 2026
Bachem Holding AG has scheduled a Capital Markets Day for November 26, 2026, to be held as a hybrid event at The Circle Convention Center at Zurich Airport and online. The company plans to use the event to present its strategic priorities, busines...
Bachem CEO Assumes Dual Role as CCO Departs
May 5, 2026
Bachem has announced that Chief Commercial Officer Torsten Wöhr will leave the company to pursue a new professional opportunity, prompting a reshuffle at the top of the organization. Effective May 25, 2026, CEO Anne‑Kathrin Stoller will...
Bachem AGM Backs Board Proposals and Confirms CHF 0.90 Dividend
Apr 29, 2026
Bachem shareholders endorsed all proposals put forward at the 2026 Annual General Meeting, with 78.3% of voting shares represented, and approved a dividend of CHF 0.90 per share to be paid on May 6, 2026, alongside the adoption of the 2025 annual ...
Bachem Secures CHF 500 Million Credit Facility to Drive Strategic Growth
Apr 27, 2026
Bachem Holding AG has secured a CHF 500 million syndicated revolving credit facility with a five-year term, arranged by UBS Switzerland AG and a consortium of domestic and international banks, with an option to increase the facility by an addition...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.